Contact | Print version | PDF version | Send article | RSS-Feed

Intercell and its partner institutions are awarded an EU grant for targeting research and novel treatments of fungal infections
Intercell further strengthens its fungal franchise by supporting the new Christian Doppler Laboratory

24 Apr 2008 - Intercell AG announced that the joint project to develop protective treatments against fungal infections was awarded an EUgrant. Intercell is coordinating a European consortium of three academic and commercial partners within the "CanVac" project. The project aims at developing a vaccine and/or a monoclonal antibodybased therapy against infections caused by the pathogenic fungus Candida albicans.
 
CanVac was one of 41 selected projects among 125 applications submitted for the first two EuroTransBio transnational calls of the European Commission and is eligible to receive funds of EUR 1.5 m. The project is scheduled to run for three years and builds on the expertise of scientists and biotech companies in Austria and Germany.
 
Together with the Christian Doppler Research Association (CDG), Intercell AG is also supporting the newly established Christian Doppler Laboratory (CDL) in Infection Biology "PathoFUN". PathoFUN is located at the Max F. Perutz Laboratories, a joint venture of the University of Vienna and the Medical University of Vienna, Campus Vienna Biocenter. The CDL is headed by Prof. Karl Kuchler.
 
PathoFunwill focus on genomic approaches to understand fungal virulence and on developing vaccines and/or monoclonal antibodybased therapies against infections caused by fungal pathogens such as Candida and Aspergillus species.